Health Economics of Dementia

The prevalence of dementia increases greatly with age so, with increasing numbers surviving to old age, Alzheimers disease has reached epidemic proportions, and this trend will increase in the future. The disease is therefore having a significant effect on escalating health care costs. Meanwhile, drugs are being developed to alleviate the symptoms of dementia and different models of care are being tried out. All these factors have important cost implications but it has been difficult to draw any consistent conclusions from studies so far. This book will become the standard reference work in the subject. It provides a sound introduction to the disease, its epidemiology, care implications, and the development and use of drugs. It discusses the challenges of obtaining reliable data, and reviews the tools used to assess the outcomes and costs of dementia to date. It also deals with the pharmacoeconomics of the disease, making it essential reading for all those who work with patients with dementia as well as for professionals in the pharmaceutical industry. This volume is: The first major text of its type to address this important area Written by internationally well-known researchers in this field A well-constructed, comprehensive and up-to-date volume providing a wealth of information

Anders Wimo was born in 1952. He's Adjunct Professor in the Department of Neurobiology, care sciences and society at the Karolinska Institutet, Stockholm, Sweden since 2007 and a Family physician in Bergsjo (Halsingland), Sweden since 1991.

Previously: Associate Professor, department of Family Medicine, Umea University, Sweden 1995. Clinical lecturer, Primary health Care of Hälsingland, 1999-2000. Researcher, Karolinska Institutet, 1999- 2007. Family physician, Sundsvall, Sweden, 1985-1991.